P3845 - Trends of IgA Nephropathy in Patients with Cirrhosis

Raissa Nana Sede Mbakop, MD¹, Kikelomo Olaosebikan, MD¹, Arnold Forlemu, MD, MPH², Nneoma Rita Ubah, MBBS³, Vishnu Poojitha Ronda, MD², Praneeth Bandaru, MD², Saigopal R. Gujjula, ⁴, Srilaxmi Gujjula, MD², Vijay Gayam, MD², Hamsika Moparty, MD², Denzil Etienne, MD², Madhavi Reddy, MD², Dominic Amakye, MD^1
1Piedmont Athens Regional Medical Center, Athens, GA; ²Brooklyn Hospital Center, Brooklyn, NY; ³East Tennessee State University, Johnson City, TN; ⁴American University of Antigua, Coolidge, Saint John, Antigua and Barbuda

Introduction: IgA nephropathy is one of the most common primary glomerulonephritis and has been well reported in case reports and case series as a complication of chronic liver disease. The pathogenesis of IgA nephropathy in patients with chronic liver disease is not well known; it appears to be related to decreased clearance of immune complexes by Kupffer cells. An autopsy study by Sinniah et al reported IgA mesangial deposits in 36% of adults with cirrhosis in Singapore. The epidemiology of IgA nephropathy in cirrhosis patients is largely unknown in the United States. Using a nationwide inpatient database, we evaluated the prevalence of IgA nephropathy in cirrhosis and described the trends of this patient population based on demographics.

Methods: We conducted a nationwide review from 2016 to 2017 using the National Inpatient Sample (NIS) data. NIS is the largest publicly available all-payer inpatient database in the United States with more than 7 million hospital stays each year, as a part of the Healthcare Cost and Utilization Project (HCUP). Patients ≥ 18 years old with cirrhosis and IgA nephropathy were identified using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Student tests and chi square tests were used to analysis continuous and categorical variables respectively. Odds ratios (OR) and confidence intervals (CI) at 99% were reported.

Results: The number of patients with cirrhosis was 272,674. The prevalence of IgA nephropathy was 0.1% (289 cases). The mean age of cirrhotic patients with IgA nephropathy was 56.3 years. The odds of IgA nephropathy in cirrhosis appeared to increase with age till age 65. Males with cirrhosis were more likely to have IgA nephropathy compared to females (5.7% vs 3.7%, p< 0.01). The odds of having cirrhosis were higher in patients with IgA nephropathy compared to those without IgA (5.0% vs 2.2%, OR 2.29 CI 2.03-2.57). The odds of cirrhosis were significantly higher among Native Americans 13.3%, Hispanics 7.4%, and Whites 5.2% (OR 2.43 CI 2.10-2.82; OR 2.20 CI 1.65-2.95; OR 2.40 CI 1.14-5.06, respectively). Also, obesity and smoking increased the odds of having IgA nephropathy in cirrhosis (OR 2.57 CI 1.89-3.50; OR 1.99 CI 1.46-2.70, respectively).

Discussion: Male cirrhotic patients were more likely to have IgA nephropathy compared to female cirrhotic patients. The prevalence of IgA nephropathy in cirrhotic patients increased with age till age 65 and is more common in Native Americans, Hispanics, and Whites.


Disclosures:


Raissa Nana Sede Mbakop, MD¹, Kikelomo Olaosebikan, MD¹, Arnold Forlemu, MD, MPH², Nneoma Rita Ubah, MBBS³, Vishnu Poojitha Ronda, MD², Praneeth Bandaru, MD², Saigopal R. Gujjula, ⁴, Srilaxmi Gujjula, MD², Vijay Gayam, MD², Hamsika Moparty, MD², Denzil Etienne, MD², Madhavi Reddy, MD², Dominic Amakye, MD¹. P3845 - Trends of IgA Nephropathy in Patients with Cirrhosis, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.